Impact of salvage chemotherapy after immune checkpoint inhibitor for recurrent or metastatic head and neck cancer

被引：0

作者：

Matoba, Takuma ^{[1
]}

Minohara, Kiyoshi ^{[1
]}

Kawakita, Daisuke ^{[1
,7
]}

Sawabe, Michi ^{[2
]}

Takano, Gaku ^{[3
]}

Oguri, Keisuke ^{[4
]}

Murashima, Akihiro ^{[1
]}

Iwaki, Sho ^{[1
]}

Tsuge, Hiroshi ^{[1
]}

Imaizumi, Sae ^{[5
]}

Hojo, Wataru ^{[4
]}

Kondo, Ayano ^{[1
]}

Tsukamoto, Koji ^{[6
]}

Iwasaki, Shinichi ^{[1
]}

机构：

[1] Nagoya City Univ, Dept Otorhinolaryngol Head & Neck Surg, Grad Sch Med Sci, Nagoya, Japan

[2] Toyota Kosei Hosp, Dept Otorhinolaryngol, Toyota, Japan

[3] Nagoya City Univ, Dept Otorhinolaryngol, West Med Ctr, Nagoya, Japan

[4] Anjo Kosei Hosp, Dept Otorhinolaryngol, Anjo, Japan

[5] Japanese Fdn Canc Res, Dept Head & Neck Surg, Canc Inst Hosp, Tokyo, Japan

[6] Aichi Canc Ctr Hosp, Dept Head & Neck Surg, Nagoya, Japan

[7] Nagoya City Univ, Dept Otorhinolaryngol Head & Neck Surg, Grad Sch Med Sci, 1 Kawasumi,Mizuho Cho,Mizuho Ku, Nagoya, Aichi 4678601, Japan

来源：

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2024年 / 46卷 / 08期

基金：

日本学术振兴会;

关键词：

head and neck cancer; immune checkpoint inhibitor; immune-related adverse effects; paclitaxel monotherapy; salvage chemotherapy; SQUAMOUS-CELL CARCINOMA; COMBINATION; CETUXIMAB; PROGRESSION; PACLITAXEL; NIVOLUMAB;

D O I：

10.1002/hed.27643

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

BackgroundIt is unclear witch regimen is optimal as salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) monotherapy for recurrent or metastatic head and neck cancer (RM-HNC).MethodsThis study enrolled 109 patients. Overall survival (OS) and progression-free survival 2 (PFS2) were compared between patients stratified by SCT regimen.ResultsOf the 109 patients, 55 underwent SCT after the failure of ICI monotherapy. The OS of these 55 patients was longer than that of patients who did not undergo SCT. The OS and PFS2 were similar between patients treated with paclitaxel (PTX) and cetuximab (Cmab) combination and those treated with PTX monotherapy. The occurrence of irAEs did not impact PFS2 nor OS.ConclusionsSCT can improve the survival outcomes of patients with RM-HNC. In addition to PTX and Cmab, PTX monotherapy is also considered an effective SCT regimen. SCT is effective regardless of the presence or absence of irAEs.

引用

页码：1855 / 1864

页数：10

共 50 条

[31] Predicting Outcomes after Salvage Reirradiation of Recurrent Head and Neck Cancer
Sircar, M.
Koutcher, L.
Wolden, S.
Chou, J.
Zhang, Z.
Sherman, E.
Wong, R.
Kraus, D.
Pfister, D.
Lee, N.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S441 - S441
[32] Surgical Salvage of Recurrent Cancer of the Head and Neck
Mark Zafereo
[J]. Current Oncology Reports, 2014, 16
[33] Surgical Salvage of Recurrent Cancer of the Head and Neck
Zafereo, Mark
[J]. CURRENT ONCOLOGY REPORTS, 2014, 16 (05)
[34] Efficacy and Safety of Salvage Chemotherapy After Progression to Anti-PD(L)1 Agents in Patients with Recurrent/Metastatic Head and Neck Cancer
Cabezas-Camarero, Santiago
Merino-Menendez, Salome
Cabrera-Martin, Maria Nieves
Sotelo, Miguel J.
Perez-Segura, Pedro
[J]. RADIOTHERAPY AND ONCOLOGY, 2024, 192 : S136 - S137
[35] Clinical predictors for survival with the addition of chemotherapy in patients with recurrent-metastatic squamous cell carcinoma of the head and neck after progression on immune checkpoint inhibitors
Issa, M.
Klamer, B.
Bhateja, P.
Karivedu, V.
Laliotis, G.
Dibs, K.
Mladkova, N.
Pan, X.
Old, M.
Gamez, M.
Grecula, J.
Jhawar, S.
Mitchell, D.
Baliga, S.
Carrau, R.
Rocco, J.
Bonomi, M.
Blakaj, D.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S797 - S798
[36] A Case of Successful Treatment with an Immune Checkpoint Inhibitor after Head and Neck Photoimmunotherapy
Hanyu, Kenji
Okamoto, Isaku
Tokashiki, Kunihiko
Tsukahara, Kiyoaki
[J]. CASE REPORTS IN ONCOLOGY, 2024, 17 (01): : 169 - 174
[37] Prognostic Value of Inflammatory and Nutritional Biomarkers of Immune Checkpoint Inhibitor Treatment for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Sakai, Akihiro
Iijima, Hiroaki
Ebisumoto, Koji
Yamauchi, Mayu
Teramura, Takanobu
Yamazaki, Aritomo
Watanabe, Takane
Inagi, Toshihide
Maki, Daisuke
Okami, Kenji
[J]. CANCERS, 2023, 15 (07)
[38] CHEMOTHERAPY IN RECURRENT HEAD AND NECK CANCER
SIMMONDS, WP
[J]. OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 1974, 7 (01) : 205 - 215
[39] EFFICACY OF SALVAGE CHEMOTHERAPY AFTER IMMUNE CHECKPOINT INHIBITOR IN NON-SMALL CELL LUNG CANCER PATIENTS
Okamatsu, Yuki
Inoue, Shigesato
Utsumi, Takahiro
Kayukawa, Takafumi
Uryu, Kazuyasu
Inoue, Katsuhiro
Tsubouchi, Kazuya
Harada, Taishi
[J]. RESPIROLOGY, 2018, 23 : 286 - 286
[40] Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management
Wang, Haiyang
Mustafa, Abdulkadir
Liu, Shixi
Liu, Jun
Lv, Dan
Yang, Hui
Zou, Jian
[J]. FRONTIERS IN PHARMACOLOGY, 2019, 10

← 1 2 3 4 5 →